Clinical trials: Ticagrelor
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Acute Coronary Syndrome
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome (ACS) and in patients undergoing coronary revascularization and conservative strategies.
- Trial name
- AD-HOC (NCT03129867)
- Testing
- Ticagrelor
- Volunteers
- 480 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Healthy
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese
This study is a open and single center clinical trial in healthy Chinese.The objective of the study is to clarify the pharmacokinetics characteristics and antiplatelet effects of ticagrelor in Chinese and to investigate the…
- Trial name
- IGPPT (NCT03092076)
- Testing
- Ticagrelor
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Guangdong Provincial People's Hospital
Healthy
PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males
This study is to characterize the pharmacokinetic and pharmacodynamics of ticagrelor and prasugrel in healthy Korean male subjects. The study is open label, one sequence, crossover design.
- Trial name
- NCT01876797
- Testing
- ticagrelor/prasugrel
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Coronary Artery Disease, Coronary Artery Bypass Grafting
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
This randomized controlled trial aims to evaluate the impact of different durations of Ticagrelor-based dual antiplatelet therapy (DAPT) on saphenous vein graft (SVG) patency in patients undergoing coronary artery bypass grafting…
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
- Trial name
- NCT06981390
- Testing
- Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kexiang Liu, MD
Peripheral Artery Disease, Vascular Disease
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
The purpose of the study is to assess the effect of blood flow to the heart when subjects are treated with ticagrelor (Brilinta) or clopidogrel (antiplatelet drugs that stop the blood from clumping together) in patients with…
- Conditions
- Peripheral Artery Disease, Vascular Disease, Arterial Occlusion Disease, Intermittent Claudication
- Trial name
- PAD (NCT02121288)
- Testing
- Ticagrelor, clopidogrel
- Sponsor
- AstraZeneca
Myocardial Infarction
Rapid Activity of Platelet Inhibitor Drugs Study 2
The aim of the RAPID study is to evaluate the superiority rapid onset of action of Ticagrelor 360 mg LD versus Prasugrel 60 mg LD, in 50 patients with STEMI (ST segment elevation myocardial infarction) undergoing PPCI with…
- Trial name
- NCT01805570
- Testing
- Prasugrel, Ticagrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- David Antoniucci
Percutaneous Coronary Intervention
Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention
During a percutaneous coronary intervention (PCI), Fentanyl is commonly used for sedation. Ticagrelor is also routinely used as anti-platelet agent during PCI.
- Trial name
- FACTPCI (NCT03476369)
- Testing
- Fentanyl, Ticagrelor 90Mg Tablet
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- The Guthrie Clinic
Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
Prasugrel Or Ticagrelor De-escalation in NSTE-ACS
The PROTEUS study is a randomized, cross-over, open-label, pharmacodynamic trial designed to compare the antiplatelet effect of reduced maintenance doses of prasugrel and ticagrelor in stable patients who recently had…
- Conditions
- Non ST Segment Elevation Acute Coronary Syndrome, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Unstable Angina
- Trial name
- PROTEUS (NCT05779059)
- Testing
- De-escalation to ticagrelor 60 mg at day 30, De-escalation to prasugrel 5 mg at day 30, Switch to ticagrelor 60 mg at day 45
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Collegium Medicum w Bydgoszczy
Periprocedural Myocardial Infarction
Ticagrelor in Remote Ischemic Preconditioning Study
Remote ischemic preconditioning (RIPC) reduces periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) through various pathways, including an adenosine-triggered pathway.
- Trial name
- TRIP (NCT04174261)
- Testing
- Ticagrelor, Remote Ischemic Preconditioning, Clopidogrel
- Where
- Greece
- Volunteers
- 245 people
- Sponsor
- Hellenic Society of Interventional Cardiology
Brain Disease, Vertebral Artery Stenosis
A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge
To compare the incidence of the composite endpoints of non-fatal ischaemic stroke, transient ischaemia (TIA) and all-cause mortality at 12-month follow-up after implantation of Bridge for the treatment of symptomatic vertebral…
- Trial name
- NCT06301776
- Testing
- Ticagrelor
- Where
- China
- Volunteers
- 560 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
Healthy
Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor
To investigate the pharmacokinetic and pharmacodynamic interaction of dabigatran and ticagrelor under steady state conditions; to investigate the effect of staggered administration of ticagrelor loading dose on dabigatran…
- Trial name
- NCT01734772
- Testing
- dabigatran etexilate, ticagrelor
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Emergent Cardiothoracic Surgery, Bleeding
Ticagrelor CytoSorb Hemoadsorption
TISORB is a study to show that the CytoSorb device removes ticagrelor from blood during surgery in patients who need emergency surgery on their heart.
- Conditions
- Emergent Cardiothoracic Surgery, Bleeding, Drug Removal
- Trial name
- TISORB (NCT04131959)
- Testing
- CytoSorb 300 mL device
- Where
- 8 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- CytoSorbents, Inc
Coronary Artery Disease, Myocardial Ischemia
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
The new P2Y12 inhibitors prasugrel (Efient®-Effient®) and ticagrelor (Brilique®-Brilinta®) have shown promising results in the respective TRITON and PLATO trials making of prasugrel and ticagrelor recommended first line…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Stent Thrombosis
- Trial name
- ALPHEUS (NCT02617290)
- Testing
- Ticagrelor, Clopidogrel
- Where
- France
- Volunteers
- 1,900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myocardial Infarction (AMI)
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.
- Trial name
- NCT07610577
- Testing
- Clopidogrel, Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 377,753 people
- Sponsor
- Brigham and Women's Hospital
Acute Coronary Syndrome
Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese
This is a prospective, single-center study to assess the long- and short-term outcomes of ticagrelor vs clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.
- Trial name
- COSTIC (NCT03239067)
- Where
- China
- Volunteers
- 9,040 people
- Sponsor
- Tongji Hospital
Acute Myocardial Infarction
Ticagrelor De-escalation Strategy in AMI Patients
DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT…
- Trial name
- NCT04755387
- Testing
- De-escalation strategy, Conventional strategy
- Where
- South Korea
- Volunteers
- 2,312 people
- Sponsor
- Dong-A University
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Acute Coronary Syndrome, Coronary Artery Disease
Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study
Subjects presenting with probable acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study.
- Trial name
- NCT01916902
- Testing
- Ticagrelor- Delayed Administration, Ticagrelor- Immediate Administration, Optical Coherence Tomography
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Coronary Artery Disease
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease
This is a Phase 4, multicenter, open-label (blinded Pharmacodynamic PD results), randomized, 3-arm, parallel-design study of subjects with stable Coronary Artery Disease CAD.
- Trial name
- SWAP-2 (NCT01587651)
- Testing
- Prasugrel Loading Dose, Prasugrel Maintenance Dose, Ticagrelor Maintenance Dose
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo